Publication Name	World Journal of Gastroenterology
Manuscript ID	10205
Country	Taiwan

Received	2014-03-19 09:33
Peer-Review Started	2014-03-19 11:34
To Make the First Decision	2014-04-15 19:39
Return for Revision	2014-04-23 21:05
Revised	2014-05-07 22:58
Second Decision	2014-06-13 11:58
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-06-13 12:32
Articles in Press	2014-06-13 13:02
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-10-27 15:55
Publish the Manuscript Online	2014-11-10 19:10

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Downregulation of signal transducer and activator of transcription 3 by sorafenib: A novel mechanism for hepatocellular carcinoma therapy
Manuscript Source	Invited Manuscript
All Author List	Man-Hsin Hung, Wei-Tien Tai, Chung-Wai Shiau and Kuen-Feng Chen
Funding Agency and Grant Number
Corresponding Author	Kuen-Feng Chen, MD, PhD, Department of Medical Research, National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan. kfchen1970@ntu.edu.tw
Key Words	Hepatocellular carcinoma; Sorafenib; Signal transducer and activator of transcription 3; Target therapy; Kinase-independent
Core Tip	Hepatocellular carcinoma (HCC) is one of the major cancers worldwide, for which the only approved target therapy is sorafenib. In addition to its previously characterized kinase inhibition, sorafenib also acts via a kinase-independent mechanism to target signal transducer and activator of transcription 3 (STAT3) signaling in HCC cells. This review discusses these findings, adding to the knowledge concerning the mechanisms of action of sorafenib as well as exploring the potential use of STAT3 as a therapeutic target in future cancer drug development.
Publish Date	2014-11-10 19:10
Citation	Hung MH, Tai WT, Shiau CW, Chen KF. Downregulation of signal transducer and activator of transcription 3 by sorafenib: A novel mechanism for hepatocellular carcinoma therapy. World J Gastroenterol 2014; 20(41): 15269-15274
URL	http://www.wjgnet.com/1007-9327/full/v20/i41/15269.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i41.15269

Full Article (PDF)	WJG-20-15269.pdf
Full Article (Word)	WJG-20-15269.doc
Manuscript File	10205-Review.docx
Answering Reviewers	10205-Answering reviewers.pdf
Copyright License Agreement	10205-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	10205-Language certificate.pdf
Peer-review Report	10205-Peer review.pdf
Scientific Misconduct Check	10205-CorssCheck.jpg
Scientific Editor Work List	10205-Scientific editor work list.pdf